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Nifedipine vs Placebo for Treatment of Chronic  
Chilblains: A Randomized Controlled Trial
ABSTRACT
PURPOSE Nifedipine is commonly prescribed for the treatment of chilblains (per-
nio, perniosis) on the basis of observational studies and a single small, older clini-
cal trial. We aimed to confirm the proposed superiority of oral nifedipine 60 mg 
per day over placebo for treatment of chronic chilblains in primary care.
METHODS We performed a randomized, placebo-controlled, double-blind, cross-
over trial, closely following the design of the older trial. A total of 32 patients 
with chronic chilblains were randomly assigned to nifedipine (30 mg controlled 
release twice a day) or placebo. The primary outcome was patient-reported 
complaints; the secondary outcome was patient-reported disability. Both were 
assessed from daily ratings on 100-mm visual analogue scales recorded in a 
diary. We took ambient temperatures into account and checked for a carry-over 
effect, and monitored for adverse effects.
RESULTS After 6 weeks of treatment, mean scores on the visual analogue scale 
on complaints showed a nonsignificant difference of 1.84 mm (95% CI, –6.67 to 
2.99 mm) in favor of nifedipine (P = .44). Mean scores on the visual analogue 
scale on disability showed a nonsignificant difference of 0.56 mm (95% CI, –2.97 
to 4.09 mm) in favor of placebo (P = .75). There was no carry-over effect of prior 
study treatment. Nifedipine was associated with significantly lower systolic blood 
pressure and a significantly higher incidence of edema.
CONCLUSIONS In our study, nifedipine was not superior to placebo for treating 
chronic chilblains. These findings contrast with those of the older study and do 
not support routine use of nifedipine for this condition.
Ann Fam Med 2016;14:453-459. doi: 10.1370/afm.1966.
INTRODUCTION
Chilblains (pernio, perniosis) are cold-induced, painful or itching lesions on the fingers, feet, ears, or thighs. The condition occurs throughout the world during the winter months when daily mean 
temperatures drop below the range of 12oC to 15oC.1 The prevalence in 
the Netherlands as reported by the Netherlands Institute for Health Ser-
vices Research (NIVEL) varies between 0.9 per 1,000 and 1.7 per 1,000 
depending on year-to-year variation and coding issues. The condition is 
more common among women than men, with respective prevalences of 0.9 
to 2.1 per 1,000 vs 0.6 to 1.2 per 1,000 (written information provided by 
NIVEL). 
Patients with chilblains report serious restrictions in daily life and 
feel an urgent need for effective treatment.2 A review of the literature 
through March 15, 2016 revealed evidence that vitamin D3, corticosteroid-
containing cream, nifedipine, and pentoxyfylline, among a wide range 
of other therapies, are used to treat symptoms of chronic chilblains.3,4 
In an earlier study, we found that vitamin D3 was not superior to pla-
cebo, however.5 Five studies evaluating the effectiveness of nifedipine in 
patients with chilblains have been published and have concluded that the 
drug is an effective treatment. These studies included only 1 random-
ized controlled trial, having 10 patients and conducted in 1989, compared 
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nifedipine with placebo.6 The others—a pilot case 
study with 10 patients, a case series with 34 patients, a 
randomized trial comparing diltiazem with nifedipine 
in 34 patients, and a study comparing nifedipine with 
topical minoxidil in 62 patients—were not placebo 
controlled.6-8
Physicians and patients are commonly advised to 
consider the prescription of nifedipine for the treat-
ment of chronic chilblains.9-13 This advice finds support 
in a proposed disease mechanism for chilblains (ie, 
cold-induced vasospasm9,14,15) and in the results of the 
5 studies previously described.6-8 Current discussion in 
the field regarding the reliability and reproducibility of 
these studies has called into question the soundness of 
the basis for the advice, however.16
We undertook a trial to confirm the proposed 
superiority of oral administration of nifedipine 60 mg 
per day compared with placebo for the treatment of 
chronic chilblains in a primary care setting.
METHODS
Trial Design
Following the methodology of the original study by 
Rustin et al,6 we conducted a 13-week randomized, 
double-blind, placebo-controlled, cross-over trial.6 A 
washout period was not incorporated in the design 
for 3 reasons. First, the original trial did not include 
a washout period. Second, for obvious reasons, the 
study had to be completed during the winter months; 
a washout period would have resulted in too long a 
research period per patient and problems with higher 
ambient temperatures in spring. Third, the exact 
mechanism of the proposed effect of nifedipine is 
unclear, so the necessary duration of a washout period 
is uncertain. Instead of using a washout period, we 
sampled the last week of every 6-week treatment 
phase and checked for a possible carry-over effect.
Participants
The study population consisted of consecutively 
enrolled patients with chronic chilblains during the 
winters of 2010 to 2012. Patients volunteered after 
being informed of the trial by their primary care physi-
cian during consultation.
Patients were eligible for the trial if they were aged 
18 years or older and reported symptoms of chronic 
chilblains that had lasted at least 3 weeks. The diagno-
sis was confirmed by an author (I.H.S.) based on com-
monly used diagnostic criteria: symptoms emerging in 
the winter months with itching and/or painful purple-
blue discolored lesions in any of several locations 
(fingers, toes, feet, or lateral thigh) without a history 
of persistence into the summer months.1,9 Swelling and 
ulceration, and reporting of earlier episodes in previous 
winters could also be present but were not mandatory 
for diagnosis. The validity of diagnosis by this author 
has previously been demonstrated.5
We excluded patients who had a known rheumato-
logic disorder, were already using nifedipine or another 
calcium channel blocker, were pregnant or lactating, or 
had contraindications to use of nifedipine.
Our sample size calculation was based on the fol-
lowing premises related to the visual analogue scale 
(VAS) used for the trial’s primary outcome. Specifically, 
in an earlier study,5 we observed a baseline visual ana-
logue scale on complaints (VOC) score of 27.97 mm 
(SD 18.82) in a similar population. We used an estimate 
of 0.5 for the correlation between 2 scores from the 
same patient on 2 occasions.5 We considered the treat-
ment effect to be clinically relevant if patients experi-
enced a decrease in the VOC score of at least 10 mm.
On the basis of use of a t test for the difference 
between 2 dependent means, 1-tail testing, an α of 0.05, 
and a β of 0.10 (power of 90%), we calculated that we 
would need a minimum of 32 participants for the trial.
Procedures
The intervention consisted of oral administration of 30 
mg nifedipine controlled release once a day for 2 weeks 
followed by 30 mg nifedipine twice a day for another 
4 weeks. The research medication was produced and 
certified under project number AKF 1720 by the 
Department of Pharmacy and Clinical Pharmacology, 
Radboud University Medical Center, Nijmegen, The 
Netherlands. 
The pharmacy that produced the research medica-
tion used block randomization with a block size of 10 
to assign patients to 2 arms that differed with respect 
to the order of treatments: placebo first or nifedip-
ine first. Both research personnel and patients were 
blinded to arm assignment. Blinding was ensured by 
use of indistinguishable capsules for active medication 
and inactive placebo. Consecutively enrolled patients 
received medication sets with consecutive therapy 
numbers. The pharmacy released the randomization 
key only after the last patient had left the study.
In the placebo-first arm, patients received no medi-
cation for 1 week to collect baseline data (phase 0), 
followed by use of placebo once a day for 2 weeks, fol-
lowed by use of placebo twice a day for 4 weeks (phase 
1), followed by nifedipine 30 mg controlled release 
once a day for 2 weeks, followed by nifedipine 30 mg 
controlled release twice a day for 4 weeks (phase 2). In 
the nifedipine-first arm, patients received no medication 
for 1 week to collect baseline data (phase 0), followed 
by nifedipine 30 mg controlled release once a day for 2 
weeks, followed by nifedipine 30 mg controlled release 
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twice a day for 4 weeks (phase 1), followed by use of 
placebo once a day for 2 weeks, followed by use of pla-
cebo twice a day for 4 weeks (phase 2). 
Each day, we documented the mean ambient tem-
perature provided by the Royal Netherlands Meteo-
rological Institute. Patients used a diary to score the 
presence and severity of itch, pain, and disability using 
the VAS daily throughout the full research period, as 
described below. Investigators had 6 face-to-face con-
tacts with patients: at intake and at the end of weeks 
1, 3, 7, 9, and 13. During these contacts, the investiga-
tors checked diaries for completeness, assessed therapy 
compliance by counting capsules, and documented 
remaining lesions.
The Dutch Competent Authority (NL31484.091.10 
BI) and the Medical Research Ethics Committee CMO 
Arnhem-Nijmegen (CMO dossier number 2010/240) 
granted permission for this study.
Outcomes
The trial’s primary and secondary outcomes were 
patient-reported complaints (symptoms) and dis-
ability, respectively, assessed with VAS having 100-
mm ranges. Patients rated these outcomes daily and 
recorded their ratings in diaries.
The primary outcome was the difference in score 
on the VOC between nifedipine and placebo after 6 
weeks of treatment. Patients rated pain and itch sepa-
rately; we used the higher of these 2 scores at the time 
of reporting. The VOC score 
was calculated as the mean 
value for the last 7 days of 
the 6-week treatment period. 
Higher scores indicated greater 
pain or itch.
The secondary outcome 
was the difference in score on 
the visual analogue scale on dis-
ability (VOD) between nifedip-
ine and placebo after 6 weeks 
of treatment. For this outcome, 
patients rated their ability to 
function normally in daily life. 
The VOD score was also cal-
culated as the mean value of 
the last 7 days of the treatment 
period. Higher scores indicated 
greater disability.
To follow the design of the 
original study6 as closely as 
possible, investigators assessed 
the chilblain lesions during 
face-to-face contacts and rated 
redness, purpleness, edema, 
and ulceration on 100-mm VAS. We also monitored for 
adverse effects—unfavorable changes in blood pres-
sure reading and in scores for headache, dizziness, and 
peripheral edema on 100-mm VAS—at each of these 
contacts.
Statistical Analysis
We used a modified intention-to-treat analysis, includ-
ing data only of patients who began the study. We per-
formed analysis of the primary and secondary patient-
reported outcomes using the 2-stage model originally 
proposed by Grizzle17 and more recently reviewed,18 
correcting for temperature changes during the research 
period for each patient with a mixed effects model 
(Grizzle model using the mixed procedure with random 
effect, SAS PROC MIXED, SAS version 9.2; SAS Insti-
tute Inc). Investigator-assessed outcomes and adverse 
effects were analyzed using 2-sample paired t tests.
RESULTS
Patient Characteristics
The procedure used to assess and enroll patients is 
shown in Figure 1. Data for 32 patients (18 women and 
14 men) were available for analysis, and their baseline 
characteristics are shown in Table 1. The patients had a 
mean age of 53 years (SD 16.1). The mean duration of 
symptoms at intake was 6.5 weeks (SD 3.6). At baseline, 
the mean score on the VOC scale was 24.92 mm (95% 
Figure 1. Flowchart of patients in the trial.
42 patients assessed for eligibility
5  patients met 
exclusion criteriaEnrollment
37 patients randomized
Randomization
Follow-up
Analysis
18  patients assigned to 
placebo- rst arm 
17  patients received 
assigned intervention
19  patients assigned to 
nifedipine- rst arm
15  patients received 
assigned intervention 
0 patients lost to follow-up 0 patients lost to follow-up
17 patients analyzed 15 patients analyzed 
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CI, 21.70-28.13) and the mean score on the VOD scale 
was 16.11 mm (95% CI, 13.09-19.13). Eleven patients 
had possibly relevant comorbidities, 6 smoked, and 9 
used potentially relevant drugs.
Our capsule counts indicated that patients did not 
take 502 capsules (11%) of the 4,480 they had been 
assigned to take. Diaries were conscientiously com-
pleted. No face-to-face contacts were missed.
We did not find any missing data for the patient-
reported primary and secondary outcomes or for 
adverse effects. One assessment for our investigator-
assessed outcomes was missing, representing 4 VAS 
scores out of 384 to be analyzed; we did not replace 
these missing data.
Primary and Secondary Outcomes
Figure 2 shows the plots of mean VOC and VOD 
scores per week, not corrected for temperature, in each 
arm and study phase.
The mean VOC score at 6 weeks of treatment was 
11.44 mm (95% CI, 6.12-16.75 mm) with nifedipine 
treatment and 13.28 mm (95% CI, 7.96-18.59 mm) with 
placebo treatment (Table 2). This resulted in a differ-
ence between arms of 1.84 mm (95% CI, –6.67 to 2.99 
mm) in favor of nifedipine (P = .44).
The mean VOD score at 6 weeks of treatment was 
4.65 mm (95% CI, 1.65-7.65 mm) with nifedipine treat-
ment and 4.09 mm (95% CI, 10.9-7.09 mm) with pla-
cebo treatment. This resulted in a difference between 
arms of 0.56 mm (95% CI, –2.97 to 4.09 mm) in favor 
of placebo (P = .75).
Carry-Over Effect
Results of analyses assessing any carry-over effect on 
the primary outcome are shown in Table 2. The mean 
VOC score at 6 weeks of treatment was 14.07 mm 
(95% CI, 7.16-20.98 mm) in the arm given placebo first 
and 10.46 mm (95% CI, 4.16-17.14 mm) in the arm 
given nifedipine first. This resulted in a nonsignificant 
difference between arms of 3.43 mm (95% CI, –6.08 to 
12.93 mm) in favor of the nifedipine-first arm (P = .47), 
indicating no carry-over effect.
Results of analyses assessing any carry-over effect 
on the secondary outcome are shown in Table 3. The 
mean VOD score at 6 weeks of treatment 
was 4.95 mm (95% CI, 1.40-8.50 mm) in 
the placebo-first arm and 3.97 mm (95% CI, 
0.46-7.12 mm) in the nifedipine-first arm. 
This resulted in a nonsignificant difference 
between arms of 1.17 mm (95% CI, –3.72 to 
6.05 mm) in favor of the nifedipine-first arm 
(P = .63), also indicating no carry-over effect.
Investigator-Assessed Outcomes
We found no statistically significant differ-
ences between nifedipine and placebo for 
investigator-assessed redness or purpleness, 
edema, or ulceration after 6 weeks of treat-
ment (Table 3).
Adverse Effects
Mean systolic blood pressure was 134.5 mm 
Hg after 6 weeks of nifedipine use and 147.1 
mm Hg after 6 weeks of placebo use (Table 
4). The mean difference was –13.1 mm Hg 
(95% CI, –24.1 to –2.0 mm Hg), which was 
statistically significant (P = .02). The mean 
assessed peripheral edema score on the VAS 
was 12.1 mm after 6 weeks of nifedipine use 
and 2.5 mm after 6 weeks of placebo use. 
The mean difference was 9.6 mm (95% CI, 
1.1-18.1 mm), which was also statistically 
significant (P = .03). Headache and dizziness 
did not differ significantly between nifedip-
ine and placebo after 6 weeks of treatment 
(Table 4).
Table 1. Patient Characteristics at Baseline 
Characteristic
Placebo-First 
Arm 
(n = 17)
Nifedipine-First 
Arm 
(n = 15)
Age, mean, y 50 59
Sex
Women, No. 8 10
Men, No. 9 5
Chilblain symptoms    
Mean duration at intake, wk 7 6
Experiencing first episode, No. 2 2
Experienced >1 episode, No. 4 4
Experiences episode every year, No. 12 10
Mean VOC score, mma,b 25 24
Mean VOD score, mmb 17 15
Smoking, No. 3 3
Comorbidity    
Diabetes, No. 0 1
Peripheral arterial disease, No. 1 0
Raynaud phenomenon, No. 6 3
Relevant medication use    
β-blocker, No. 0 0
Nicotine replacement drug, No. 0 0
Acetylsalicylic acid, No. 0 1
ACE or angiotensin II receptor 
blocker, No.
3 2
ACE = angiotensin-converting enzyme; VOC = visual analogue scale on complaints; 
VOD = visual analogue scale on disability. 
a The higher of either the visual analogue scale itch score or the visual analogue scale pain 
score.
b Scores measured on 100-mm scales where higher values indicate more complaints (symp-
toms) or greater disability.
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DISCUSSION
We did not find any clinically 
or statistically significant dif-
ferences in favor of nifedipine 
over placebo for the treatment 
of chronic chilblains. The dif-
ference in patient-reported 
complaints (symptoms) tended 
to favor nifedipine, while the 
difference in patient-reported 
disability tended to favor pla-
cebo. Nifedipine was associated 
with a lower systolic blood 
pressure and a higher incidence 
of edema. We did not find any 
significant carry-over effect of 
prior treatment on the primary 
or secondary outcome. Differ-
ences between the nifedipine-
first and placebo-first arms 
tended to favor the former.
Strengths and Limitations
The main strength of this study 
is our effort to confirm the 
findings of the original random-
ized controlled trial that led 
to the current general advice 
to consider nifedipine for the 
treatment of chronic chilblains. 
No such confirmation study 
had previously been performed. 
We followed the design of the 
original study as closely as pos-
sible but tripled the number of 
patients based on our sample 
size calculation. Improving on 
the original design, we fur-
ther took into account ambi-
ent temperature as a major 
confounder.3,19,20
We assessed primary and 
secondary outcomes with VAS 
scores for pain, itch, and disabil-
ity using patient diaries. These 
scales are generally used and 
validated for this purpose.21-23
Patient compliance was 
good. Although 11% of assigned 
capsules were not taken, known 
adverse effects of nifedipine 
(lower systolic blood pressure 
and more edema) were still seen 
during nifedipine treatment. 
Table 2. Primary and Secondary Outcomes Corrected for Differences  
in Ambient Temperature
Outcome
Score, mma 
Test of Fixed 
Effects
Mean (95% CI) Difference (95% CI) F Value
P Value  
(r>F) 
Primary: VOC score
Treatment
Nifedipine 11.44 (6.12 to 16.75) – – –
Placebo 13.28 (7.96 to 18.59) –1.84 (–6.67 to 2.99) 0.61 .44
Arm
Placebo first 14.07 (7.16 to 20.98) – – –
Nifedipine first 10.65 (4.16 to 17.14) 3.43 (–6.08 to 12.93) 0.54 .47
Temperature –  – 3.62 .07
Secondary: VOD score 
Treatment
Nifedipine 4.65 (1.65 to 7.65) – – –
Placebo 4.09 (1.09 to 7.09) 0.56 (–2.97 to 4.09) 0.10 .75
Arm
Placebo first 4.95 (1.40 to 8.50) – – –
Nifedipine first 3.79 (0.46 to 7.12) 1.17 (–3.72 to 6.05) 0.24 .63
Temperature  – – 1.63 .21
VAS = visual analog scale; VOC = visual analogue scale on complaints; VOD = visual analogue scale on disability.
a On a visual analogue scale in week 6 of treatment. Scores measured on 100-mm scales where higher values 
indicate more complaints (symptoms) or greater disability.
Figure 2. Patient-reported scores for complaints (VOC) and disability 
VOD (not corrected for temperature) for each arm and study phase.
VAS = visual analogue scale; VOC = visual analogue scale on complaints; VOD = visual analogue scale on disability.
Notes: Scores measured on 100-mm scales where higher values indicate more complaints (symptoms) or greater 
disability. Phase 0: no-treatment baseline; phase 1: first assigned treatment; phase 2: second assigned treatment. 
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Patients conscientiously completed their diaries and 
did not miss any face-to-face contacts.
Because of the recruitment method used for our 
trial, we can generalize our findings to patients with 
idiopathic chronic chilblains in general practice.
Almost one-half of our participants reported hav-
ing Raynaud phenomenon as a comorbidity (Table 1). 
This high figure may suggest some sort of relationship 
between chronic chilblains and Raynaud phenom-
enon. We did not exclude participants who had this 
condition because it can be easily distinguished from 
chronic chilblains.24-26 It is unlikely that the high preva-
lence of Raynaud phenomenon affected our results as 
placebo-controlled trials indicate that nifedipine and 
other calcium channel blockers are effective for treat-
ing that condition.27
We found a remarkable reduction of chilblains 
symptoms during placebo treatment that may have 
several explanations. First, the placebo effect may 
have been responsible.28 Second, almost all studies on 
chilblains report that 60% to 70% of the patients expe-
rience an improvement.3 None of these studies thor-
oughly corrected for the influence of exposure to cold 
and other confounders, however. Third, we did not 
collect information about therapy received for previous 
episodes, but in our opinion, prior therapy is unlikely 
to have influenced our results. Last, we did not ask our 
patients not to change their habits during the study, 
which raises the possibility of a Hawthorne effect.29 
We are unable to exclude such an effect caused by 
patients’ own efforts to alleviate their symptoms by 
changing habits during the study. 
Nevertheless, we consider it to 
be unlikely because nearly all 
patients with chilblains have 
already tried almost everything 
to relieve their symptoms.2 In our 
opinion, the reduction of symp-
toms during placebo treatment 
likely reflects both a placebo 
effect and the natural course of 
the disease.
Comparison With Existing 
Literature
Our findings contrast with 
those of the original random-
ized controlled trial by Rustin et 
al.6 We did not reproduce their 
clear positive effect of nifedipine 
compared with placebo either 
in patient diary data or in our 
investigator assessment of the 
chilblains. Our findings are also 
at odds with the results of the other, non–placebo-
controlled studies on the use of nifedipine to treat 
chronic chilblains.6-8
Implications for Practice
Our randomized controlled trial failed to confirm 
effectiveness of nifedipine for the treatment of chronic 
chilblains in general practice and showed evidence that 
its use in this context may cause harm. These findings 
underscore the importance of rigorous evaluation of 
treatments, with adequate numbers of patients and 
control for potential confounders, before widespread 
adoption. Current advice to prescribe nifedipine for 
chilblains should be revisited, and clinicians should 
weigh and discuss with patients evidence on the poten-
tial benefits and harms of various treatment options 
before making treatment decisions. 
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/content/14/5/453.
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Table 3. Investigator-Assessed Outcomes After 6 Weeks of Treatment
Outcomea Placebo Nifedipine 
Mean Difference 
(95%CI)
P  
Value
Redness score, mean, mm 17.0 18.3 1.9 (–3.8 to 7.6) .50
Purpleness score, mean, mm 6.6 4.9 –1.5 (–5.6 to 2.6) .47
Edema score, mean, mm 4.9 7.8 3.2 (–0.5 to 6.9) .09
Ulceration score, mean, mm 0.0 0.2 0.2 (–0.2 to 0.6) .33
a Assessed using 100-mm visual analogue scales where higher values indicate greater severity.
Table 4. Adverse Effects After 6 Weeks of Treatment
Outcomea Placebo Nifedipine
Mean Difference 
(95% CI)
P  
Value
Systolic blood pressure,  
mean, mm Hg
147.1 134.5 –13.1 (–24.1 to –2.01) .02
Headache score, mean, mma 2.2 6.9 4.7 (–0.8 to 10.3) .09
Dizziness score, mean, mma 1.6 4.7 3.1 (–1.0 to 7.2) .13
Peripheral edema score,  
mean, mma
2.5 12.1 9.6 (1.1 to 18.1) .03
a Assessed using 100-mm visual analogue scales where higher values indicate greater severity.
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